Cincinnati, Ohio
Phase 3 cancer trials in Cincinnati, OH
60 Phase 3 cancer studies are recruiting participants at sites in Cincinnati as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cincinnati at a glance
- 60 studies are recruiting at a site in Cincinnati.
- By phase: Phase 2/3 (3), Phase 3 (57).
- By sponsor: industry (37), university, hospital or other (21), government (2).
- By research area: Lung Cancer (22), Breast Cancer (15), Prostate Cancer (10), Lymphoma (8), Pancreatic Cancer (3), Melanoma (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Cincinnati
Basic details from each study's public record (the 30 most recently updated of 60). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
- Registry record
- NCT06966700 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- The Christ Hospital · University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT03418961 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study sites
- Good Samaritan Hospital · Oncology Hematology Care, Inc.
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · The Christ Hospital
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT06748222 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020)
- Registry record
- NCT07060807 · updated
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- American Society of Clinical Oncology
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06377852 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lung cancer studies recruiting in Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Study site
- Clinical Study Sites
- Registry record
- NCT06767514 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center ( Site 0119)
- Registry record
- NCT06623422 · updated
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
- Registry record
- NCT06345729 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Oncology Hematology Care
- Registry record
- NCT06646276 · updated
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06561386 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- Oncology_Hematology Care Clinical Trials,LLC
- Registry record
- NCT07144280 · updated
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- The Christ Hospital
- Registry record
- NCT07361497 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT04181060 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- USO - Oncology Hematology Care
- Registry record
- NCT06119581 · updated
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- UC Medical Center - Oncology
- Registry record
- NCT06452277 · updated
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study sites
- The Christ Hospital Cancer Center · University of Cincinnati Medical Center
- Registry record
- NCT06712316 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Prostate cancer studies recruiting in Cincinnati
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- BioNTech SE
- Study site
- Oncology/Hematology Care, Inc.
- Registry record
- NCT07365995 · updated
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati
- Registry record
- NCT04423211 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Cincinnati
- Registry record
- NCT07164443 · updated
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Cincinnati
- Registry record
- NCT07225946 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Melanoma studies recruiting in Cincinnati
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lymphoma studies recruiting in Cincinnati
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002)
- Registry record
- NCT06717347 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT05675410 · updated
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Phase 3
- Ages 1 and older
- All sexes
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT07223021 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study sites
- Oncology Hematology Care Clinical Trials · University of Cincinnati
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT03150693 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT07215910 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Cincinnati
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT07562152 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Ask about studies near Cincinnati
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
139 studies recruiting across 67 cities.
Columbus
65 studies recruiting.
Cleveland
62 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections